PMID- 16913268
OWN - NLM
STAT- MEDLINE
DCOM- 20061020
LR  - 20190608
IS  - 1088-5412 (Print)
IS  - 1088-5412 (Linking)
VI  - 27
IP  - 3
DP  - 2006 May-Jun
TI  - Safety and clinical relief over 1 year with triamcinolone acetonide 
      hydrofluoroalkane-134a nasal aerosol in patients with perennial allergic 
      rhinitis.
PG  - 243-7
AB  - The intranasal corticosteroid triamcinolone acetonide (TAA) is an effective 
      treatment for allergic rhinitis (AR). A new hydrofluoroalkane-134a 
      (HFA)-propelled formulation (TAA-HFA) has been approved recently. This study 
      assessed the safety and efficacy of TAA-HFA in patients with perennial AR over 1 
      year. A total of 396 patients aged 12-69 years with perennial AR (PAR) enrolled 
      in this 1-year, open-label study. Patients received TAA-HFA, 220 microg, once 
      daily for 2 weeks before adjusting their dose to 440 or 110 microg once daily as 
      needed to control symptoms. Doses were standardized to 440 microg across all 
      patients at approximately 4 months. Physical examinations, vital signs, and 
      laboratory measurements were conducted at baseline, 6 months, and study end. 
      Patient and physician global symptom evaluations were performed at visits 3-10. 
      Patients recorded any adverse events (AEs) on daily diary cards. Of the 396 
      patients enrolled, 349 (88.1%) reported AEs. The most frequently reported AEs 
      were pharyngitis, rhinitis, local reactions, headache, epistaxis, and sinusitis. 
      Most AEs were mild to moderate in intensity; 34 patients discontinued because of 
      AEs. There were no clinically relevant changes in physical examinations, vital 
      signs, or laboratory measurements. A total of four serious AEs were reported; all 
      were recorded as not related to study drug. Mean patient and physician scores of 
      symptom relief showed significant relief from week 2 (visit 3) through the final 
      visit. Long-term administration of TAA-HFA, 440 microg, exhibited a good safety 
      and tolerability profile, while providing moderate-to-complete symptom relief as 
      rated by patients and physicians.
FAU - Weber, Richard
AU  - Weber R
AD  - Department of Medicine, Allergy Division, National Jewish Medical and Research 
      Center, 1400 Jackson Street, Denver, CO 80206-2762, USA. weberr@njc.org
FAU - Garcia, Jorge
AU  - Garcia J
FAU - Faruqi, Rab
AU  - Faruqi R
FAU - Banerji, Donald
AU  - Banerji D
FAU - Georges, George
AU  - Georges G
CN  - 405 Investigator Group
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 0 (Aerosol Propellants)
RN  - 0 (Glucocorticoids)
RN  - 0 (Hydrocarbons, Fluorinated)
RN  - F446C597KA (Triamcinolone Acetonide)
RN  - R40P36GDK6 (apaflurane)
SB  - IM
MH  - Administration, Intranasal
MH  - Adolescent
MH  - Adult
MH  - *Aerosol Propellants
MH  - Aged
MH  - Child
MH  - Drug Administration Schedule
MH  - Female
MH  - Glucocorticoids/*administration & dosage/adverse effects
MH  - Humans
MH  - *Hydrocarbons, Fluorinated
MH  - Male
MH  - Middle Aged
MH  - Rhinitis, Allergic, Perennial/*drug therapy
MH  - Treatment Outcome
MH  - Triamcinolone Acetonide/*administration & dosage/adverse effects
EDAT- 2006/08/18 09:00
MHDA- 2006/10/21 09:00
CRDT- 2006/08/18 09:00
PHST- 2006/08/18 09:00 [pubmed]
PHST- 2006/10/21 09:00 [medline]
PHST- 2006/08/18 09:00 [entrez]
AID - 10.2500/aap.2006.27.2848 [doi]
PST - ppublish
SO  - Allergy Asthma Proc. 2006 May-Jun;27(3):243-7. doi: 10.2500/aap.2006.27.2848.